EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P3
Near historical low
vs 5Y Ago
-4.6x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -21.63% |
| Q3 2025 | 22.01% |
| Q2 2025 | -14.48% |
| Q1 2025 | 10.06% |
| Q4 2024 | -2.73% |
| Q3 2024 | 1.52% |
| Q2 2024 | -9.26% |
| Q1 2024 | 23.39% |
| Q4 2023 | 3.61% |
| Q3 2023 | -23.07% |
| Q2 2023 | -4.24% |
| Q1 2023 | 3.94% |
| Q4 2022 | -5.37% |
| Q3 2022 | -1.37% |
| Q2 2022 | 1.31% |
| Q1 2022 | -10.49% |
| Q4 2021 | 26.75% |
| Q3 2021 | 13.43% |
| Q2 2021 | 9.92% |
| Q1 2021 | -7.02% |
| Q4 2020 | 4.72% |
| Q3 2020 | 1.69% |
| Q2 2020 | -12.85% |
| Q1 2020 | 8.11% |
| Q4 2019 | -4.90% |
| Q3 2019 | 0.36% |
| Q2 2019 | 1.49% |
| Q1 2019 | 28.63% |
| Q4 2018 | 18.71% |
| Q3 2018 | 36.20% |
| Q2 2018 | 151.29% |
| Q1 2018 | -7.73% |
| Q4 2017 | -3.89% |
| Q3 2017 | -1.98% |
| Q2 2017 | 8.16% |
| Q1 2017 | -16.34% |
| Q4 2016 | -11.72% |
| Q3 2016 | 23.68% |
| Q2 2016 | 13.21% |
| Q1 2016 | 14.83% |